Oruka Therapeutics (ORKA) slides 8.2% as investors digest recent $700M equity raise

Oruka Therapeutics, Inc. (ORKA) is down 8.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be post-financing pressure following Oruka’s recently completed upsized $700 million common-stock offering, which can weigh on shares as new supply is absorbed and hedges unwind. The drop may also reflect profit-taking and repositioning after a busy catalyst window that included both clinical updates and a new technology collaboration.

Details:

Oruka completed an upsized underwritten public offering of 9,660,000 shares priced at $72.50 per share, increasing the share count and creating near-term dilution overhang.

In an April 30, 2026 Form 8-K tied to the offering, Oruka also included a preliminary (unaudited) estimate of about $496 million in cash, cash equivalents, and investments as of March 31, 2026, which some traders may reassess alongside the much larger post-offering balance sheet.

Halozyme Hypercon and Oruka entered a global exclusive collaboration and license agreement for Hypercon™ technology for ORKA-001, with an option for an additional target; while strategically positive, such deals can introduce questions on economics, timelines, and execution.

This could also be because biotech risk appetite weakened broadly, amplifying selling in higher-beta names.

Sources:

U.S. SEC, Oruka Therapeutics Investor Relations, PR Newswire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ORKA Insider Trading Activity

$ORKA insiders have traded $ORKA stock on the open market 29 times in the past 6 months. Of those trades, 0 have been purchases and 29 have been sales.

Here’s a breakdown of recent trading of $ORKA stock by insiders over the last 6 months:

JOANA GONCALVES (Chief Medical Officer) has made 0 purchases and 15 sales selling 35,641 shares for an estimated $1,438,945.
LAURA LEE SANDLER (Chief Operating Officer) has made 0 purchases and 12 sales selling 23,600 shares for an estimated $882,780.
LAWRENCE OTTO KLEIN (Chief Executive Officer) sold 1,729 shares for an estimated $71,407
ARJUN AGARWAL (Senior Vice President, Finance) sold 395 shares for an estimated $16,313

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive ORKA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ORKA Hedge Fund Activity

We have seen 102 institutional investors add shares of $ORKA stock to their portfolio, and 32 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PARADIGM BIOCAPITAL ADVISORS LP added 1,710,316 shares (+inf%) to their portfolio in Q4 2025, for an estimated $51,839,677
CABLE CAR CAPITAL, LP removed 1,600,000 shares (-80.0%) from their portfolio in Q4 2025, for an estimated $48,496,000
BLACKROCK, INC. added 1,334,864 shares (+60.6%) to their portfolio in Q4 2025, for an estimated $40,459,727
BRAIDWELL LP removed 1,297,555 shares (-93.9%) from their portfolio in Q4 2025, for an estimated $39,328,892
STATE STREET CORP added 731,819 shares (+112.2%) to their portfolio in Q4 2025, for an estimated $22,181,433
VANGUARD GROUP INC added 676,865 shares (+38.1%) to their portfolio in Q4 2025, for an estimated $20,515,778
DEEP TRACK CAPITAL, LP removed 493,271 shares (-18.6%) from their portfolio in Q4 2025, for an estimated $14,951,044

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$ORKA Analyst Ratings

Wall Street analysts have issued reports on $ORKA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

UBS issued a "Buy" rating on 01/07/2026
BTIG issued a "Buy" rating on 11/13/2025
Jefferies issued a "Buy" rating on 11/13/2025

To track analyst ratings and price targets for $ORKA, check out Quiver Quantitative's $ORKA forecast page.

$ORKA Price Targets

Multiple analysts have issued price targets for $ORKA recently. We have seen 10 analysts offer price targets for $ORKA in the last 6 months, with a median target of $93.0.

Here are some recent targets:

Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $120.0 on 04/29/2026
Michael Yee from UBS set a target price of $100.0 on 04/28/2026
Etzer Darout from Barclays set a target price of $160.0 on 04/28/2026
Julian Harrison from BTIG set a target price of $151.0 on 04/27/2026
Martin Fan from Wedbush set a target price of $85.0 on 04/15/2026
Yatin Suneja from Guggenheim set a target price of $125.0 on 04/13/2026
David Risinger from Leerink Partners set a target price of $86.0 on 03/16/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.